ClinicalTrials.gg
CompletedNCT00469456Updated Dec 24, 2009Results posted

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

A Phase 4 interventional study of Memantine and placebo in Alzheimer's Disease, sponsored by Forest Laboratories. Completed at 25 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2009-12-24.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
7th of 34
265 · median 90
Started
2007
with 5 others
Phase 4
21 of 34
none open now
Registered
9th of 34
by date
Lead sponsor
4 of 34
Forest Laboratories

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 7th largest by enrollment, is one of 6 that started in 2007, is one of 21 in phase 4, and was the 9th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • memantine
  • Alzheimer's Disease
  • communication
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients, 50 years or older, native English speakers, meeting National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD with a (MMSE) score of 10 to 19 at Screening and Baseline

Exclusion criteria

Exclusion Criteria:

  • Current --Fourth Edition (DSM-IV) Axis I disorder other than AD
  • Previous imaging results not consistent with the diagnosis of AD
  • Modified Hachinski Ischemia Score greater than 4
  • Evidence of other neurologic disorders
  • systemic disease
  • A known or suspected history of alcohol or drug abuse in the past 5 years
  • Taking excluded medication
  • Previous treatment with commercial memantine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
265 participants (actual)

Study arms

  • Active comparator
    1

    Memantine 20mg (10mg twice daily) oral administration for 12 weeks

    Drug: Memantine

  • Placebo comparator
    2

    Placebo oral administration twice daily for 12 weeks

    Drug: placebo

Interventions

  • Memantine 20mg (10mg twice daily) oral administration for 12 weeks

    Also known as: Namenda®

  • Drugplacebo

    Placebo oral administration twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12

    FLCI is a standardized \& validated instrument for evaluating functional communication in pts with moderate-to-severe Alzheimer's that can be used to obtain Baseline information \& to track patients' capabilities thereafter. The FLCI evaluates 10 areas: greeting and naming, answering questions, writing, sign comprehension, object-to-picture matching, word reading and comprehension, following commands, pantomime, gesture, and conversation. The FLCI total score ranges from 0 to 87, a higher score denotes better functional communication, and takes approximately 30 minutes to complete.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12

    The ASHA FACS assesses \& measures functional communication skills of adults with speech, language, \& cognitive communication disorders. The measure, which comprises 43 items and takes approximately 20 minutes to complete, assesses functional communication in four areas: social communication; communication of basic needs; reading, writing, and number concepts; and daily planning. Total score of subdomains \[Social Communication and Communication of Basic Needs\] ranges from 0-196. A higher score denotes better communication.

    Time frame: Baseline to Week 12

07

Results

Posted Dec 7, 2009

Participant flow

The recruitment period was from May 24, 2007 to July 29, 2008 at 25 centers in three countries \[14 in Australia, 3 in New Zealand, 8 in South Africa\].

Participant flow — Overall Study
MilestonePlaceboMemantine
Started129135
Completed120131
Not completed94
Withdrew: Adverse event43
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject41

Outcome measures

PrimaryChange From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12

FLCI is a standardized \& validated instrument for evaluating functional communication in pts with moderate-to-severe Alzheimer's that can be used to obtain Baseline information \& to track patients' capabilities thereafter. The FLCI evaluates 10 areas: greeting and naming, answering questions, writing, sign comprehension, object-to-picture matching, word reading and comprehension, following commands, pantomime, gesture, and conversation. The FLCI total score ranges from 0 to 87, a higher score denotes better functional communication, and takes approximately 30 minutes to complete.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12
Units on a scalePlaceboMemantine
Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12-0.6 ± 0.590.7 ± 0.57
Statistical analysis
  • Placebo vs Memantine · ANCOVA · p = 0.070 · Mean difference (final values): 1.3 · 95% CI -0.1 to 2.8
SecondaryChange From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12

The ASHA FACS assesses \& measures functional communication skills of adults with speech, language, \& cognitive communication disorders. The measure, which comprises 43 items and takes approximately 20 minutes to complete, assesses functional communication in four areas: social communication; communication of basic needs; reading, writing, and number concepts; and daily planning. Total score of subdomains \[Social Communication and Communication of Basic Needs\] ranges from 0-196. A higher score denotes better communication.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12
Units on a scalePlaceboMemantine
Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12-5.3 ± 2.060.5 ± 1.99
Statistical analysis
  • Placebo vs Memantine · ANCOVA · p = 0.022 · Mean difference (final values): 5.9 · 95% CI 0.9 to 10.9

Adverse events

Collected over Occurring on or after the date of the first dose of double-blind study medication and within 30 days of the date of last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—13/129 (10.1%)2/129 (1.6%)
Memantine—4/135 (3%)7/135 (5.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboMemantine
SyncopeNervous system disorders2/1290/135
Urinary Tract InfectionInfections and infestations2/1290/135
Atrioventricular Block First DegreeCardiac disorders1/1290/135
Bile Duct StoneHepatobiliary disorders1/1290/135
Cerebellar InfarctionNervous system disorders1/1290/135
ConstipationGastrointestinal disorders1/1290/135
FallInjury, poisoning and procedural complications1/1290/135
Femur FractureInjury, poisoning and procedural complications1/1290/135
Gastric UlcerGastrointestinal disorders1/1290/135
Gastrointeritis YersiniaInfections and infestations1/1290/135
Most frequent other events
Most frequent other events
EventPlaceboMemantine
DizzinessNervous system disorders2/1297/135

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboMemantineTotal
<=64 years191332
65-74 years335184
75-84 years5956115
>=85 years181533
Age Continuous
Age Continuous(years)PlaceboMemantineTotal
Mean75.1 ± 8.6874.8 ± 8.0574.9 ± 8.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMemantineTotal
Female7480154
Male5555110
Region of Enrollment
Region of Enrollment(participants)PlaceboMemantineTotal
Australia5555110
South Africa5862120
New Zealand161834
08

Study locations

25 sites
  • Forest Investigative Site
    East Gosford, New South Wales 2250, Australia
  • Forest Investigative Site
    Hornsby, New South Wales 2077, Australia
  • Forest Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Forest Investigative Site
    Newcastle, New South Wales 2300, Australia
  • Forest Investigative Site
    Randwick, New South Wales 2031, Australia
  • Forest Investigative Site
    Chermside, Queensland 4032, Australia
  • Forest Investigative Site
    Toowoomba, Queensland 4350, Australia
  • Forest Investigative Site
    Adelaide, South Australia 5000, Australia
  • Forest Investigative Site
    Woodville, South Australia 5011, Australia
  • Forest Investigative Site
    Box Hill, Victoria 3182, Australia
  • Forest Investigative Site
    Frankston, Victoria 3199, Australia
  • Forest Investigative Site
    Heidelberg West, Victoria 3081, Australia
  • Forest Investigative Site
    Kew, Victoria 3101, Australia
  • Forest Investigative Site
    Perth, Western Australia 6001, Australia
  • Forest Investigative Site
    Christchurch, 8022, New Zealand
  • Forest Investigative Site
    North Shore, 0622, New Zealand
  • Forest Investigative Site
    Timaru, 8022, New Zealand
  • Forest Investigative Site
    George, E. Cape 6529, South Africa
  • Forest Investigative Site
    Port Elizabeth, E. Cape 6014, South Africa
  • Forest Investigative Site
    Johannesburg, Gauteng 2052, South Africa
  • Forest Investigative Site
    Johannesburg, Gauteng 4001, South Africa
  • Forest Investigative Site
    Pretoria, Gauteng 0182, South Africa
  • Forest Investigative Site
    Durban, KZ-Natal 4001, South Africa
  • Forest Investigative Site
    Cape Town, W. Cape 7500, South Africa
  • Forest Investigative Site
    Cape Town, W. Cape 7530, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2007
First posted
May 4, 2007
Start
Apr 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 7, 2009
Last update
Dec 24, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00469456
First posted
May 4, 2007
Start date
Apr 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 7, 2009
Last update
Dec 24, 2009

Study contacts

F C Potocnik
principal investigator
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion